A predictive, modeling‐based screening tool to enrich amyloid beta positivity in a cognitively normal sample
A predictive, modeling‐based screening tool to enrich amyloid beta positivity in a cognitively normal sample
Abstract Background As β‐amyloid (Aβ) targeted clinical trials have had questionable benefit in treating patients with early symptomatic Alzheimer’s disease, treatment would presumably be most effective if administered during the disease’s preclinical phase. PET scans, while highly sensitive to AD pathology, are less practical for screening a large, cognitively normal …